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Objectives: In vivo experimentation is costly and time-consuming, and presents a major bottleneck in anti-
tuberculosis drug development. Conventional methods rely on the enumeration of bacterial colonies, and it
can take up to 4 weeks for Mycobacterium tuberculosis to grow on agar plates. Light produced by recombinant
bacteria expressing luciferase enzymes can be used as a marker of bacterial load, and disease progression can
be easily followed non-invasively in live animals by using the appropriate imaging equipment. The objective of
this work was to develop a bioluminescence-based mouse model of tuberculosis to assess antibiotic efficacy
against M. tuberculosis in vivo.
Methods: We used an M. tuberculosis strain carrying a red-shifted derivative of the firefly luciferase gene
(FFlucRT) to infect mice, and monitored disease progression in living animals by bioluminescence imaging
before and after treatment with the frontline anti-tuberculosis drug isoniazid. The resulting images were
analysed and the bioluminescence was correlated with bacterial counts.
Results: Using bioluminescence imaging we detected as few as 1.7×103 and 7.5×104 reporter bacteria ex vivo
and in vivo, respectively, in the lungs of mice. A good correlation was found between bioluminescence and bac-
terial load in both cases. Furthermore, a marked reduction in luminescence was observed in living mice given
isoniazid treatment.
Conclusions: We have shown that an improved bioluminescent strain of M. tuberculosis can be visualized by
non-invasive imaging in live mice during an acute, progressive infection and that this technique can be used
to rapidly visualize and quantify the effect of antibiotic treatment. We believe that the model presented
here will be of great benefit in early drug discovery as an easy and rapid way to identify active compounds
in vivo.
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Introduction
Mycobacterium tuberculosis remains one of the most successful
bacterial pathogens, despite ongoing efforts to curb the tubercu-
losis (TB) epidemic, and poses a severe threat to public health.
Confounding factors include the concurrent HIV epidemic, and
the increasing incidence of infections with multidrug-resistant
(MDR) and extremely drug-resistant (XDR) strains.1 It is evident
that more effective control measures are urgently needed, and
in vivo experimentation is an essential tool in addressing this
goal. At a basic research level, the appropriate use of animal
models can help to improve our understanding of host–
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pathogen interactions. In translational research, in vivo testing is
an absolute requirement for pre-clinical evaluation of new drug
and vaccine candidates before these can advance along the de-
velopment pipeline. However, in vivo experimentation is costly
and time-consuming, and presents a major bottleneck in drug
and vaccine development. This is partly due to the long replica-
tion time of M. tuberculosis; conventional methods rely on the
enumeration of bacterial colonies, which can take 3–4 weeks
to form on solid medium. Therefore, novel approaches to accel-
erate efficacy assessment of new control measures are urgently
required.
Bioluminescence, the production of light by the action of luci-
ferase enzymes on their cognate substrates, offers the potential
to accelerate the development and testing of new TB control
measures. Light produced by recombinant bacteria expressing
such luciferase enzymes can be used as a marker of bacterial
load, and disease progression can be easily followed non-
invasively in live animals by using the appropriate imaging equip-
ment. Indeed, this approach has been successfully used for in
vivo studies of a wide variety of bacteria.2 The most extensively
used luciferase is LuxAB, naturally found in luminous bacteria
such as Photorhabdus luminescens, Vibrio sp. and Photobacter-
ium sp. The luciferase is encoded by a five-gene operon, which
also includes genes for the synthesis of the luciferase substrate,
a long-chain aldehyde. Therefore, recombinant expression of the
whole operon renders the bacterial host autoluminescent. The
firefly luciferase (FFluc) has occasionally been used in bacterial
research and is very popular in viral and eukaryotic studies.2
The genes for the synthesis of its substrate, D-luciferin, are
unknown and therefore it has to be administered exogenously
before imaging. Fortunately the substrate is innocuous and the
light produced by FFluc is of a wavelength more appropriate for
in vivo imaging than that from LuxAB.3,4
In TB research, bioluminescent reporter technology has been
successfully exploited for in vitro applications for more than two
decades. In particular, bioluminescence has been harnessed as
a surrogate biomarker for mycobacterial numbers and viability,5,6
and bioluminescent mycobacterial reporter strains have been
utilized for high-throughput, real-time screening of antimyco-
bacterial agents.7 – 10 More recently this powerful technology has
also been applied to real-time, non-invasive in vivo imaging of
mycobacterial infection. The first demonstration of in vivo
imaging of bioluminescent Mycobacterium bovis BCG in immuno-
deficient mice was provided in 2009.11 However, as this strain only
carried the luxAB genes encoding the luciferase, it required the
administration of the toxic aldehyde substrate, decanal, for
visualization of the mycobacteria. Furthermore, this work was
carried out with the attenuated vaccine strain M. bovis BCG, and
not with virulent M. tuberculosis. Other researchers have utilized
bioluminescent Mycobacterium ulcerans in a mouse footpad
model.12 In 2010 we published the first report of the use of
bioluminescent M. tuberculosis,13 demonstrating the successful
detection of mycobacteria expressing either FFluc or Lux in the
lungs of infected mice. It was also the first time that the complete
lux operon had been successfully expressed in mycobacteria.
More recently, autoluminescent M. tuberculosis (expressing the
complete bacterial luciferase operon) has been exploited in
proof-of-concept studies to monitor drug and vaccine efficacy
using a tube luminometer to measure bioluminescence from
organ homogenates and from mice.14
Here, we report on the development of an improved FFluc re-
porter (FFlucRT) for in vivo imaging of M. tuberculosis. We demon-
strate the in vivo visualization of the improved FFlucRT reporter
strain in severe combined immunodeficiency (SCID) mice, and
provide evidence that this system could be applied to high-
throughput in vivo testing of drug efficacy. In addition, we
explore ways to further enhance the reporter system.
Materials and methods
Bacterial strains and growth conditions
M. tuberculosis H37Rv and Mycobacterium smegmatis mc2155 were
grown on 7H11 agar (BD Diagnostics) supplemented with 0.5% glycerol,
10% oleic acid/albumin/dextrose/catalase (OADC) (BD Diagnostics) and
appropriate antibiotics. Liquid cultures of M. tuberculosis were grown
with shaking in 7H9 broth (BD Diagnostics) supplemented with 0.05%
Tween-80, 0.2% glycerol, 10% OADC and appropriate antibiotics. Luria–
Bertani (LB) medium was used for culturing Escherichia coli. All the
strains were grown at 378C. The following antibiotics were added when
appropriate: ampicillin [100 mg/L (Sigma)] and kanamycin [25 mg/L for
mycobacteria and 50 mg/L for E. coli (Sigma)].
Construction of FFlucRT reporter plasmids and strains
The plasmids used in this study are described in Table S1 (available as Sup-
plementary data at JAC Online). We designed a modified version of FFluc,
designated FFlucRT (GenBank accession number KC688279), containing
nine amino acid substitutions. The corresponding M. tuberculosis
codon-optimized DNA fragment was synthesized by DNA 2.0. We then
used the synthetic DNA construct as a PCR template to incorporate a
STOP codon and an XbaI site at the 3′ end of fflucRT (sense primer: 5′-
CTTTCGCCCGGGCTAATTAG-3′; antisense primer: 5′-AGGCTTCTAGATCAC
AATTTCGACTTGCCACC-3′. The restriction site is underlined and the STOP
codon is in bold). An EcoRI-XbaI PCR product was cloned into pUC18 and
the sequence was confirmed by DNA sequencing. To obtain pMV306G13+
FFlucRT, fflucRTwas cloned into pMV306hsp as an EcoRI-SalI insert and the
hsp60 promoter replaced with the Mycobacteriummarinum G13 promoter
by digestion with NotI-EcoRI as previously described.13 The integrase-free
reporter plasmid pMV306DIG13+FFlucRT was produced by deleting the int
gene from pMV306G13+FFlucRT by inverted PCR using the Phusionw Site-
Directed Mutagenesis Kit (Thermo Scientific) and primers IntUp
(5′-TCTTGTCAGTACGCGAAGAACCAC-3′) and IntLw (5′-GTCCATCTTGTTGT
CGTAGGTCTG-3′). The deletion was confirmed by digesting with SphI and
the sequence of PG13 and fflucRT partially checked by DNA sequencing.
The reporter strain M. tuberculosis pMV306G13+FFlucRT was produced
by electroporation of M. tuberculosis with the corresponding vector. To
obtain the integrase-free reporter strain, M. tuberculosis was co-trans-
formed with pMV306DIG13+FFlucRT and pBS-Int,15 a suicide plasmid
that carries the integrase gene but no attachment site, and is therefore
lost from the bacterium. The presence of the reporter plasmid in both
strains and the absence of the integrase gene from pMV306DIG13+
FFlucRT were confirmed by PCR.
In vitro bioluminescence assays
D-Luciferin (Gold BioTechnologyw) was prepared in distilled water at
3×104 mg/L. The stock was stored at 2208C and diluted in broth
medium or Dulbecco’s PBS (D-PBS) (without calcium or magnesium) im-
mediately before use. Working solutions were kept on ice in the dark
during preparation. D-Luciferin was added at a final concentration of
150 mg/L and bioluminescence was measured for 10 s using a micro-
plate reader (Luminoskan Ascent, Thermo Scientific). Bioluminescence
was expressed as relative light units (RLUs).
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Bioluminescence emission spectra
Bioluminescence emission spectra were obtained by imaging M. smeg-
matis cultures expressing FFluc and FFlucRT with the IVISw Spectrum
system (Caliper Life Sciences). Briefly, 50 mL of each culture was inocu-
lated in triplicate in a 96-well opaque black plate, 50 mL of 300 mg/L
luciferin was added to each well, and the plate was imaged using a set
of filters (20 nm bandpass) from 500 to 800 nm on the auto-exposure
setting. Bioluminescence in each well was quantified using the region
of interest (ROI) tool in the Living Image software program (reported
as photons/s).
In vivo studies
Experiments were performed in accordance with the Animals (Scientific
Procedures) Act (1986) and were approved by the local ethics review
committee. Barrier-bred female 6–12 week old CB-17 SCID mice
(Charles River UK Ltd) were anaesthetized by intraperitoneal injection of
a mixture of ketamine (100 mg/kg body weight; Ketaset; Fort Dodge
Animal Health) and xylazine (10 mg/kg body weight; Rompun; Bayer)
and infected with wild-type (WT) or bioluminescent M. tuberculosis in
20 mL of PBS via the intranasal route. In each experiment one group of
mice was treated with isoniazid starting on day 19 post-infection. Isoni-
azid was dissolved in 40% sucrose at a final concentration of 5000 mg/L
and filter sterilized. Mice were given daily doses of 25 mg/kg body weight
of isoniazid by oral gavage. Control mice were given daily doses of 40%
sucrose by oral gavage.
Assessment of bioluminescence [photons/s/cm2/steradian (sr)] from
living animals was performed using an IVISw Spectrum system. Prior to
bioluminescent imaging, mice were injected via the intraperitoneal
route with 500 mg/kg body weight of D-luciferin dissolved in sterile
D-PBS together with ketamine and xylazine as above. Mice were con-
tained in a large airtight box for safety considerations and placed into
the imaging chamber of the IVISw Spectrum imaging system with the
stage heated to 378C. A greyscale reference image was taken under
low illumination prior to quantification of emitted photons over 5 min
using the software Living Image version 3.2. Bioluminescence within spe-
cific regions of individual mice was also quantified using the ROI tool in
the Living Image software program (given as photons/s).
At specific timepoints and immediately after performing the in vivo
imaging, animals were culled by cervical dislocation while still under an-
aesthesia and the lungs and spleens were removed aseptically. Ex vivo
imaging of the lungs and spleens as intact organs was performed as
above, placing the organs in a sterile, black, 24-well plate with clear
bottom contained in the airtight box. Finally, to determine the bacterial
burden, the organs were homogenized by mechanical disruption in PBS
with 0.05% Tween and viable counts were determined by serial dilution
plating on Middlebrook 7H11 agar.
Plasmid stability
To assess the stability of the reporter vectors in vitro, the bioluminescent
M. tuberculosis strains were grown in liquid medium with no antibiotic se-
lection and passaged into fresh medium fortnightly. Every 4 weeks ap-
propriate dilutions of the culture were plated on 7H11 to obtain at
least 100 isolated colonies. These colonies were then inoculated in
200 mL of 7H9 medium in opaque, white, 96-well plates and the lumines-
cence was read after 5–7 days of incubation, as described above. To
prevent sample evaporation during incubation, 200 mL of sterile water
was added to all outer perimeter wells. A sterile control without bacteria
was prepared for each assay and the luminescence reading from this
control was used as the background reading. Bacterial viability was deter-
mined by adding 30 mL of sterile 0.01% resazurin to all wells and incubat-
ing for a further 24 h. A change in colour from blue (oxidized state) to
pink (reduced state) indicated growth of the bacteria. Plasmid stability
in vivo was evaluated in a similar way, but using colonies isolated from
organ homogenates.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5 software. For
both cfu and luminescence, data from different groups at specific time-
points were analysed by a Mann–Whitney test. To assess the relationship
between cfu and luminescence, a Pearson correlation calculation was
performed and the resulting Pearson r values and two-tailed P values
were reported. Linear regression analysis was used to determine the
relationship between cfu and bioluminescence. P values ,0.05 were
considered to be statistically significant.
Results
Development of an improved FFluc reporter
We had previously developed FFluc-based reporters for use in
mycobacteria.13 To enhance the limit of detection of FFluc activity
in vivo, in the present work we modified the protein in two ways.
First, we introduced previously described mutations shown to
increase bioluminescence intensity, namely Ile423Leu,
Asp436Gly and Leu530Arg.16 Second, to produce a thermostable
red-emitting luciferase, we incorporated the following mutations:
Ser284Thr, Thr214Ala, Ala215Leu, Ile232Ala, Phe295Leu and
Glu354Lys.17 The resulting reporter, named FFlucRT (GenBank ac-
cession number KC688279), was not significantly brighter than
the original FFluc, but it demonstrated an emission spectrum
shift towards the red in comparison with the FFluc reporter; the
maximum emission shifted from 560 nm for FFluc to 620 nm for
FFlucRT (Figure S1, available as Supplementary data at JACOnline).
In order to maximize the expression of the new reporter we
used an M. tuberculosis codon-optimized synthetic gene together
with an improved Shine Dalgarno sequence, both of which have
proved useful in increasing FFluc signal in mycobacteria.13 The re-
porter was expressed under control of the PG13 promoter,
18,19
which provided the optimal combination of signal strength and
reporter plasmid stability (data not shown).
We next assessed the growth kinetics and luminescence of
M. tuberculosis expressing the FFlucRT reporter. M. tuberculosis
pMV306G13+FFlucRT demonstrated identical in vitro growth
kinetics to M. tuberculosis WT (Figure 1). The luminescence
levels of the FFlucRT-expressing M. tuberculosis strain were
similar to that produced by the FFluc-carrying strain (Figure 1).
However, whereas the FFluc reporter signal decreased upon
entry into stationary phase (Figure 1), this was not the case for
the FFlucRT reporter for which luminescence remained stable in
the stationary phase (Figure 1). FFlucRT therefore demonstrated
a better overall correlation between luminescence and bacterial
numbers [as measured by optical density at 600 nm (OD600)].
Evaluation of the reporter in vivo
Having established that the M. tuberculosis FFlucRT reporter strain
has similar in vitro growth kinetics to M. tuberculosis WT, we went
on to investigate in vivo growth kinetics. To this end, immunodefi-
cient mice were intranasally infected with parental M. tuberculosis
WTand FFlucRT reporter strains and the bacterial load in the lungs
was determined by serial dilution plating of organ homogenates.
Andreu et al.
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Both strains showed similar growth kinetics with an 1000-fold
increase in lung bacterial burden within 3 weeks (Figure 2), at
which point the experiment was terminated because the
humane endpoint (20% weight loss) was reached. Furthermore,
both WT and FFlucRT strains disseminated to the spleens to a
similar extent, reaching levels of 6.1×104 (+3.7×104) and
2.5×104 (+1.7×104) cfu/spleen, respectively, by the end of the
experiment. Altogether these results indicate that expression of
the FFlucRT reporter does not incur a fitness cost.
We next assessed the ability to detect bacteria expressing the
FFlucRT reporter in vivo. Infected mice were imaged at multiple
timepoints after administering intraperitoneal luciferin. The back-
ground level of luminescence was estimated by imaging mice
inoculated with M. tuberculosis WT. Bioluminescence above back-
ground levels was detected in the thorax region of live animals
infected with M. tuberculosis pMV306G13+FFlucRT at day 13
post-infection, when the lung bacterial load was estimated to
be 105 cfu (Figure 3a–c). The increase in thorax-localized lumi-
nescence paralleled the increase in lung cfu (Figure 3c). A weak
signal was also observed in the abdomen of WT- and
FFlucRT-infected mice when the scale of the images was
adjusted to a low setting (Figure 3b). Upon dissection of the
mice we confirmed that the signal came from the livers. This
signal is probably the result of the high concentration of luciferin
used together with the high uptake and probable metabolism of
luciferin in the liver.20,21
At selected timepoints we also determined the bioluminescent
signal in lungs and spleens ex vivo. We detected bioluminescence
in all lungs harvested from mice infected with M. tuberculosis
pMV306G13+FFlucRT as early as day 1 post-infection
(Figure 4a), when the total lung bacterial load was 1.7×103 cfu.
As expected, the bioluminescent signal increased over the
course of the infection, corresponding to the increase in cfu
(Figure 4b).
Ex vivo bioluminescence in spleens was detected at 18 days
post-infection (Figure 5a), which was also the earliest timepoint
when bacteria could be cultured from this organ. The bacterial
load in the spleens at this timepoint was 2.8×103 cfu (Figure 5b).
Taken together, these results demonstrated that as few as
103 and 105 cfu of bioluminescent M. tuberculosis could be
detected ex vivo and in vivo, respectively, in the lungs of mice,
and that both ex vivo and in vivo bioluminescence corresponded
to bacterial load.
Application to drug testing
The results described above suggested that this technology
might be a useful tool to accelerate in vivo drug testing. As
proof-of-concept, we treated infected mice with isoniazid, part
of frontline anti-TB drug treatment, or sucrose as the carrier
control, and followed the response to treatment in real time
using bioluminescence imaging. In vivo imaging of live mice
revealed a marked reduction in luminescence as early as day 4
of isoniazid treatment in three out of five mice (day 22 post-
infection, Figure 6a). By day 10 of treatment (day 28 post-
infection), we observed an 8.8-fold reduction in luminescence
in the thorax of all infected mice. The differences in lumines-
cence levels were statistically significant between the beginning
and end of treatment (Figure 6a and c). The observed reduction
in luminescence was corroborated by plating lung homogenates
after 10 days of isoniazid treatment, which confirmed a reduc-
tion in bacterial burden in line with the luminescent measure-
ments for this organ (Figure 6c). At this point the bacterial load
was just 7.5×104 cfu/lung and yet bioluminescence was clearly
detectable non-invasively in the thorax of live mice (Figure 6b
and c), representing the lowest number of bacteria that we
were able to detect in vivo.
Similar results were obtained ex vivo; we observed a statistically
significant reduction in lung luminescence levels over 10 days of
isoniazid treatment. This was closely paralleled by the reduced
bacterial organ burden as revealed by cfu counts (Figure 6d).
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Figure 2. Growth of M. tuberculosis in SCID mice is not affected by the
expression of the FFlucRT reporter. SCID mice were infected with
1.1×104 cfu of M. tuberculosis pMV306G13+FFlucRT or with 1.0×104 cfu
of the parental M. tuberculosis WT via the intranasal route. Bacterial
burden was determined by serial dilution plating of organ homogenates.
Each point on the graph represents the median and range (n¼5 mice).
This result is representative of two independent experiments. Statistical
significance was evaluated by the Mann–Whitney test and those found
to be significant (P,0.05) are indicated with an asterisk.
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Figure 1. FFlucRT bioluminescence correlates with cell density. Cultures of
M. tuberculosis pMV306G13+FFlucRT, M. tuberculosis pMV306G13+FFluc
and M. tuberculosis H37Rv (WT) were inoculated at an OD of 0.01, and
the OD and luminescence were measured over 9 days. The plots
represent the means and standard deviations of values for three
independent cultures, and values are plotted on a logarithmic scale. BL,
bioluminescence.
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These results provide proof-of-principle that the M. tuberculosis
pMV306G13+FFlucRT reporter strain can be applied to rapid in
vivo testing of new anti-TB compounds.
Sensitivity of M. tuberculosis bioluminescence imaging
and correlation with bacterial load
The correlation between bioluminescence and bacterial burden
was statistically analysed by Pearson correlation. A good correl-
ation was found between bioluminescence in the thorax of live
mice and cfu in the lungs [r(9)¼0.958, two-tailed P value
,0.0001; Figure 7a]. In addition, bioluminescence measured in
the lungs ex vivo strongly correlated with bacterial burden in
these organs [r(14)¼0.946, two-tailed P value ,0.0001;
Figure 7b]. A linear regression analysis was performed to calculate
the detection limit of this assay (Figure 7a and b). Because any
detectable amount of reporter bacteria should produce higher
amounts of bioluminescence than WT bacteria, the signal (Y)
was set based on the average amount of bioluminescence
detected in the thorax and the lungs of mice infected with WT
M. tuberculosis. The average background bioluminescence mea-
sured was 2×105 photons/s in live mice and 1.5×104 photons/s
in the lungs ex vivo; therefore, the threshold for the signal (Y)
was arbitrarily set to 4×105 and 3×104 photons/s, respectively.
From this, the detection limit in live mice was calculated as
4.4×104 cfu. Similarly the detection limit for excised lungs was
calculated as 1.2×102 cfu.
Optimization of plasmid stability
One parameter that could impact on the sensitivity of biolumines-
cent reporter strains is stability of the reporter plasmid. To
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Figure 3. In vivo imaging of M. tuberculosis infection. SCID mice were infected with 1.1×104 cfu of M. tuberculosis pMV306G13+FFlucRT or with
1.0×104 cfu of M. tuberculosis WT via the intranasal route. (a) Mice were injected intraperitoneally with 500 mg/kg D-luciferin, and images were
acquired using an IVISw Spectrum system. *M. tuberculosis WT-infected mice; all others infected with M. tuberculosis pMV306G13+FFlucRT. Day 1
and 6 images were very similar. Only day 1 is shown here. (b) The scale on the images shown here has been adjusted to demonstrate that a
detectable signal was observed in the lungs of all five mice as early as day 13. M. tuberculosis pMV306G13+FFlucRT-infected mice are the same
mice as shown in (a). The signal in the abdomen of the mice comes from the liver due to background luminescence from the luciferin substrate. (c)
Bioluminescence in the thorax was quantified for each mouse at each timepoint and compared with cfu data at corresponding timepoints. Each
point on the graph represents the median and error (n¼5 mice). This result is representative of two independent experiments. Bckg, background
luminescence (2×105 photons/s). This figure appears in colour in the online version of JAC and in black and white in the printed version of JAC.
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determine whether this was a contributing factor in the experi-
ments described here, we assessed the stability of integrated
pMV306G13+FFlucRT following in vivo growth. Bioluminescence
of colonies recovered from organ homogenates was measured
to calculate the percentage of colonies retaining the ability to
express the FFlucRT reporter. First, we examined plasmid stability
in colonies recovered from the lungs of SCID mice, and found
that by the end of the experiment (day 22 post-infection),
87.2% of colonies isolated from lungs of sucrose-treated mice
retained a functional FFlucRT reporter.
To determine whether drug treatment or different organ envir-
onments could influence plasmid stability, we compared colonies
recovered from isoniazid-treated versus sucrose-treated mice as
well as different organs. Bacteria recovered from isoniazid-treated
mice demonstrated similar plasmid stability (94.9%) to those
recovered from sucrose-treated control animals (87.2%). We
also observed similar levels of plasmid stability in bacteria recov-
ered from spleens (data not shown).
In summary, we found that within the first 3 weeks of infection
10% of bacteria had lost the ability to express the FFlucRT
reporter. PCR amplification of selected colonies indicated that
non-bioluminescent colonies had lost the integrated plasmid
(data not shown). To address this shortcoming we developed
more stable reporters by constructing integrase-free reporter plas-
mids. We subsequently introduced an integrase-free reporter into
M. tuberculosis, creating the M. tuberculosis pMV306DIG13+
FFlucRT strain (DI FFlucRT). We confirmed that the DI FFlucRT
strain grew identically to both WT M. tuberculosis and M. tubercu-
losis pMV306G13+FFlucRT in vitro, and that the DI FFlucRT strain
produced equivalent levels of bioluminescence to the FFlucRTcoun-
terpart. Crucially, in vitro the DI FFlucRTstrain exhibited substantially
superior reporter stability in comparison with the FFlucRT parent
strain. Following 3 months of in vitro growth (with fortnightly sub-
culturing), 40% of colonies recovered from the M. tuberculosis
pMV306G13+FFlucRT strain had lost the ability to luminesce. This
was in sharp contrast to the pMV306DIG13+FFlucRT strain,
where only 1 of 118 colonies did not luminesce, demonstrating
that.99% of colonies retained a functional bioluminescent report-
er after 3 months of in vitro growth (P,0.0001).
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Figure 4. Ex vivo bioluminescence in infected lungs. (a) Images of lungs
harvested from the mice in Figure 3 were acquired using an IVISw
Spectrum system at multiple timepoints following infection.
*M. tuberculosis WT-infected mice; all others infected with M. tuberculosis
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Figure 5. Ex vivo bioluminescence in infected spleens. (a) Images of
spleens harvested from the mice in Figure 3 infected with M. tuberculosis
pMV306G13+FFlucRT were acquired using an IVISw Spectrum system at
multiple timepoints following infection. (b) Bioluminescence (measured
as photons/s) was quantified for each spleen and compared with cfu
data at corresponding timepoints. Each point on the graph represents
the median and range (n¼4–5 mice). Bckg, background luminescence
(1.3×104 photons/s); LoD, limit of detection (100 cfu). This figure
appears in colour in the online version of JAC and in black and white in
the printed version of JAC.
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Discussion
The urgent need for new anti-TB drugs requires innovative
approaches for accelerating the drug development pipeline. Ef-
ficacy testing in animal models constitutes an early and signifi-
cant bottleneck partly because bacterial burden is measured as
cfu recovered from organ homogenates and it can take up to
4 weeks for M. tuberculosis to grow on agar plates. Molecular
imaging can provide an alternative readout for disease
progression and treatment efficacy. Bioluminescence imaging
is particularly suitable for the rapid screening of drug candidates
in mice thanks to its short acquisition times, the fact that up to
5 mice can be imaged simultaneously, and that it is
highly sensitive and quantitative. We have previously optimized
three bioluminescent reporters for use in mycobacteria and
proved that Lux and FFluc are suitable for in vivo imaging.13
While the former yields autoluminescent mycobacteria, the
latter requires the administration of the substrate luciferin.
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Figure 6. Effects of drug treatment were detected non-invasively in live mice by bioluminescent imaging. M. tuberculosis pMV306G13+FFlucRT-
infected SCID mice were treated daily with 25 mg/kg isoniazid (INH) by oral gavage from day 19 post-infection (pi). A control group was treated
with sucrose. (a) To visualize the effect of INH treatment, mice were injected intraperitoneally with 500 mg/kg D-luciferin, and images were acquired
using an IVISw Spectrum system. (b) The scale on the images shown here has been adjusted to demonstrate that a detectable signal was
observed in the lungs of all five mice on day 28 post-infection, when the bacterial load was just 7.5×104 cfu/lung. The mice are the same mice as
shown in (a). The reduction in bacterial burden quantified in live mice (c) or lungs ex vivo (d) by bioluminescent imaging was confirmed by
enumerating lung cfu. Each point on the graphs represents the median and range (n¼3–5 mice). Bckg, background luminescence in live mice
(2×105 photons/s). The background luminescence in the lungs ex vivo (1.5×104 photons/s) is outside the axis limits. Statistical significance was
evaluated by the Mann–Whitney test and those found to be significant (P,0.05) are indicated with an asterisk. This figure appears in colour in the
online version of JAC and in black and white in the printed version of JAC.
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However, this is non-toxic, easily administered and the signal
obtained is much brighter than with Lux. Here, we demon-
strated that bioluminescence imaging can be used as a non-
invasive approach to visualize and quantify M. tuberculosis infec-
tion and drug treatment in live mice using a further improved
FFluc reporter.
A key challenge in bioluminescence imaging is light absorp-
tion by tissues. This is mainly caused by haemoglobin, which
absorbs in the blue and green part of the visible spectrum,
whereas red light can travel through several centimetres of
tissue.4 The WT FFluc produces yellow-green light. In order to
improve FFluc for in vivo imaging, we introduced six mutations
known to produce a thermostable red-emitting FFluc17 plus
three mutations that had been previously shown to increase bio-
luminescence intensity more than 10-fold.16 The resulting re-
porter strain, M. tuberculosis FFlucRT, emitted red light as
expected, but it was not significantly brighter in vitro than the
strain expressing the original FFluc. Although the precise mech-
anism underlying this is unknown, it is possible that the ‘red
mutations’ adversely affected the ‘bright phenotype’. Nonethe-
less, the 60 nm shift on the emission spectra of the luciferase
constitutes a vast improvement for in vivo imaging.
Interestingly, the bioluminescence produced by FFlucRT-
expressing M. tuberculosis correlated with cell density in vitro
during both the exponential and stationary phases, whereas
the signal produced by FFluc decreased during the stationary
phase. It is thought that this decrease in FFluc bioluminescence
reflects the metabolic state of the cells in the stationary phase
since the luciferase uses ATP as a cofactor. In this sense, the un-
altered bioluminescence of FFlucRT during the stationary phase
could be explained by an increased affinity of the enzyme for
ATP in comparison with FFluc. Alternatively, it could also be
due to a longer half-life of the protein as a result of increased
thermostability, a property that has been shown to correlate
with imaging sensitivity.22 A more detailed study would be ne-
cessary to establish how the nine mutations may have affected
the ATP affinity and the thermostability of the enzyme, but this is
beyond the scope of this work.
The FFlucRT-expressing M. tuberculosis retained full virulence
in vivo. Importantly, we were able to non-invasively detect the
microorganisms in the lungs of live mice as early as 2 weeks
after infection, when the bacterial load was estimated to be
around 105 cfu per lung and the signal was 5.8×105 photons/s.
A similar level of bioluminescence (5.2×105 photons/s) was
measured in the thorax of live mice after 10 days of treatment
with isoniazid 4 weeks post-infection, when the bacterial
burden was 7.5×104 cfu/lung. This is the lowest number of bac-
teria that we were able to detect in live mice and is very close to
the calculated limit of detection of 4.4×104 cfu/lung. To our
knowledge, this is by far the lowest limit of detection of M. tuber-
culosis infection achieved so far using bioluminescence imaging.
Furthermore, as few as 103 cfu were detected ex vivo in lungs
and spleens with a calculated limit of detection in the lungs of
just 1.2×102 cfu.
Significantly, both in vivo and ex vivo bioluminescence imaging
allowed the rapid assessment of antibiotic treatment efficacy,
with a decrease in bioluminescence observed in vivo after just
7 days of treatment, giving a total turnaround time for the assay
of 3–4 weeks. In this study, we used immunocompromised
mice since they allow a faster growth of M. tuberculosis and there-
fore a high bacterial load can be achieved in a shorter time. In add-
ition, using the immunocompromised mouse model allows
measurement of the anti-tubercular efficacy exclusively due to
the drug action and independent of the immune system contribu-
tion. Results could be obtained in an even shorter time if biolumin-
escence imaging is used together with previously described rapid
drug-testing assays.23 In these assays, treatment is started 1 day
after infection with a high dose (105 cfu), and results are assessed
after 7 days of treatment. Using such a high infection dose of the
reporter strain described here would potentially allow assessment
of treatment efficacy non-invasively in real time from day 1. If im-
munocompetent mice were used, an infection dose of around
103 cfu would be needed to detect the bacteria non-invasively,
considering that M. tuberculosis typically grows 3–4 log10 before
the onset of adaptive immunity. In low-dose infection models in
which mice are challenged with 50–100 cfu, the highest bacterial
load achieved in the lungs would be very close to the limit of detec-
tion, but we would expect the infection to be visualized and quan-
tified in the dissected lungs. Another parameter that would need
to be assessed is the effect of the immune response on biolumin-
escence production in terms of metabolic stress caused by the
immune system or substrate availability in granulomatous lesions.
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Figure 7. In vivo and ex vivo bioluminescence correlates with bacterial
burden. Correlation of cfu in the lungs and bioluminescence in the
thorax (a) or in the harvested lungs (b) of infected mice shown in
Figures 3 and 6. The number of cfu X for a given bioluminescence
measurement Y is described by the equation shown, which was
obtained from linear regression analysis.
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We have used isoniazid, which is often utilized as a control in
drug screening experiments,24 to provide a proof-of-concept of
the feasibility of our bioluminescence–mouse model to assess
drug efficacy. With this drug we have observed a similar effect
on bioluminescence and cfu; however, other drugs with different
mechanisms of action could affect these two readouts to differ-
ent degrees, as has previously been reported for ethambutol,
linezolid and moxifloxacin.14 Even so, any compound with an
effect on cfu will very likely also affect bioluminescence. There-
fore, bioluminescence imaging could be used for the initial
rapid screening of compounds, with the best candidates selected
for further studies using cfu analysis.
We have previously utilized M. tuberculosis expressing fluores-
cent reporters in vitro and in vivo.25,26 The advantage of using
fluorescent reporters is that, in contrast to bioluminescent report-
er systems, samples can be analysed by fluorescence microscopy
and flow cytometry. Furthermore, as fluorescent reporters do not
use ATP or FMNH2 as cofactors, they are not as tightly linked to bac-
terial metabolism. This should prove advantageous for studying
dormant M. tuberculosis in vivo. However, fluorescent reporter
proteins require excitation light to generate a photonic signal.
Unfortunately, the autofluorescence of endogenously produced
fluorophores such as keratin, porphyrins, NAD(P)H and collagen,
and absorption by haemoglobin and melanin in some cases
generally results in worse signal-to-noise ratios than observed
for bioluminescence, making fluorescence imaging much less
sensitive. Indeed, when we applied these fluorescent reporter
strains to test anti-TB drugs in vivo, the limits of detection
were 100–1000-fold higher (8×107 cfu/lung in vivo and
2×105 cfu/lung ex vivo).26 While bioluminescent and fluorescent
reporters can be considered complementary, depending on the
particular experimental question being addressed, the biolumin-
escence method presented here represents a major improvement
for drug screening in vivo since it can be used for non-invasive
imaging of live mice and has a much better sensitivity both
in vivo and ex vivo.
A different approach for in vivo imaging of mycobacteria was
described in 2010 by Kong et al.27 In this case a fluorogenic sub-
strate for the mycobacterial b-lactamase was used. This reaction
results in the production of fluorescence that can be detected
in vivo. The authors claim that as few as 104 cfu/lung can be
detected using this method. However, this particular experiment
was done with the non-pathogenic BCG rather than with M. tuber-
culosis, and only a very dim signal could be seen close to the
animal axilla. In addition, to get a good correlation between
signal and cfu the imaging has to be performed 24 h post-
substrate administration; at later timepoints substrate accumula-
tion leads to a similar level of fluorescence independent of
bacterial numbers. In fact, it takes 72–96 h for the signal to com-
pletely fade, which means that repeated imaging cannot be per-
formed at shorter intervals. In contrast, using our reporter strain
the imaging can be performed every few hours if required, and
the signal is stronger and can be clearly localized in the lungs.
One parameter that could negatively affect the limit of detec-
tion for our reporter strain is the loss of the reporter vector in vivo
in the absence of antibiotic selection. In fact, we found that
.10% of the colonies recovered from the lungs of infected
SCID mice 3 weeks post-infection had lost the plasmid. It is
known that the loss of L5-based integration vectors is due to
site-specific excision catalysed by the integrase present in
these vectors.15 Plasmid loss can be prevented by providing the
integrase gene separately on a non-replicating suicide vector.
Using this strategy we managed to increase the stability of the
vector from 60% to .99% in vitro following 3 months of
culture with no antibiotic selection. Future work will evaluate
the use of this strain in vivo regarding virulence and the limit
of detection using bioluminescence imaging.
In summary, we have shown that an improved M. tuberculosis
bioluminescent strain can be visualized by non-invasive imaging
in live mice during an acute, progressive infection. Furthermore,
we prove that this method can be used to visualize and quantify
the effect of antibiotic treatment. If necessary, the sensitivity of
the technique can be increased by imaging dissected organs ex
vivo, offering a more rapid readout than traditional growth-based
assays. We believe that the model presented here can be of great
use in early drug discovery as an easy and rapid way to identify
active compounds in vivo.
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